
Shares of Cytokinetics, Inc. (NASDAQ:CYTK) are trading sharply higher Tuesday after the biopharmaceutical company presented new data highlighting the long-term safety and efficacy of its investigational drug, aficamten, at the European Society of Cardiology Congress 2025. Here’s what investors need to know.
What To Know: The company announced several key findings from multiple clinical trials for the cardiac myosin inhibitor, which is being developed to treat hypertrophic cardiomyopathy (HCM), a disease that causes thickening of the heart muscle.